APP and Alzheimer disease: The present study clearly demonstrated that 4 month treatment of DNLA ameliorated the AD pathology in aged APP/PS1 transgenic mice, as evidenced by behavioral tests, morphology, and reduced Aβ deposition in the hippocampus.